One company that is starting to turn the heads of investors is the Gainesville, Florida based Quick-Med Technologies. Quick-Med is a life sciences company that is developing innovative technologies for the healthcare and consumer markets. One of the major assets of Quick-Med is NIMBUS technology which employs a safe, eco-friendly active agent that remains in full concentration on any of safer substrates.
Quick-Med has earned national recognition for the development of their NIMBUS applications in several other advanced wound dressing formats including adhesives, foams, hydrogels, films, and hydrocolloids. Today, Quick-Med took a major step towards enhancing their future with the announcement they have been granted a third U.S. Patent for the NIMBUS(NYSE:R) Technology.
The patent received from the United States Patent and Trademark Office (USPTO) is No. 7,709,694 and will allow the NIMBUS(R) polymeric antimicrobial technology to be applicable to a variety of base materials including woven and nonwoven fabrics which will allow the young company to branch out into new endeavors within their sector.
Leading the way at Quick-Med Technologies is J. Ladd Greeno. Greeno serves as the CEO of the growing corporation. Commenting on what this patent will mean to the future of Quick-Med, Greeno was quoted as saying, “This patent issuance significantly enhances the current protection for our proprietary NIMBUS technology, further validating its innovative nature. Further, the patent underscores our leadership in developing the first non-leaching antimicrobial available in a wound dressing. While other antimicrobial dressings rely on the release of chemicals into the wound bed that can impede the wound healing process, a non-leaching antimicrobial dressing represents a significant improvement.”
To learn more about Quick-Med Technologies, visit their website at quickmedtech.com
Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net
Disclosure: NO POSITIONS